Skip to main content
PMC home page
Canadian Family Physician logoLink to Canadian Family Physician
. 1999 Jul;45:1698-700, 1703-5.

Valacyclovir. New indication: for genital herpes, simpler administration.

PMCID: PMC2328354  PMID: 10424269

Abstract

Valacyclovir, the metabolic precursor of acyclovir, is now approved for treatment and prevention of genital infection with herpes simplex viruses. The clinical file is bulky and methodologically sound. For treatment of a first episode of genital herpes, a large comparative trial has shown that valacyclovir (1 g twice a day) is as effective as acyclovir (200 mg five times a day) when given for 10 days. For treating recurrences, two trials show that valacyclovir is as effective as acyclovir (200 mg five times a day) with a treatment period of 5 days. A daily dose of 1 g of valacyclovir is as effective as 2 g daily. Valacyclovir can be administered once a day. For prevention among patients with frequent recurrences, the efficacy of valacyclovir (500 mg/d in a single dose) has been proven in a placebo-controlled trial lasting 4 months. In these trials, valacyclovir and acyclovir were both well tolerated, with no major differences between the two drugs.

Full text

PDF
1703

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodsworth N. J., Crooks R. J., Borelli S., Vejlsgaard G., Paavonen J., Worm A. M., Uexkull N., Esmann J., Strand A., Ingamells A. J. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med. 1997 Apr;73(2):110–116. doi: 10.1136/sti.73.2.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bodsworth N. J., Crooks R. J., Borelli S., Vejlsgaard G., Paavonen J., Worm A. M., Uexkull N., Esmann J., Strand A., Ingamells A. J. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group. Genitourin Med. 1997 Apr;73(2):110–116. doi: 10.1136/sti.73.2.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fife K. H., Barbarash R. A., Rudolph T., Degregorio B., Roth R. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group. Sex Transm Dis. 1997 Sep;24(8):481–486. doi: 10.1097/00007435-199709000-00007. [DOI] [PubMed] [Google Scholar]
  4. Patel R., Bodsworth N. J., Woolley P., Peters B., Vejlsgaard G., Saari S., Gibb A., Robinson J. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. Genitourin Med. 1997 Apr;73(2):105–109. doi: 10.1136/sti.73.2.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Patel R., Bodsworth N. J., Woolley P., Peters B., Vejlsgaard G., Saari S., Gibb A., Robinson J. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. Genitourin Med. 1997 Apr;73(2):105–109. doi: 10.1136/sti.73.2.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Spruance S. L., Tyring S. K., DeGregorio B., Miller C., Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med. 1996 Aug 12;156(15):1729–1735. [PubMed] [Google Scholar]
  7. Spruance S. L., Tyring S. K., DeGregorio B., Miller C., Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med. 1996 Aug 12;156(15):1729–1735. [PubMed] [Google Scholar]
  8. Tyring S. K., Douglas J. M., Jr, Corey L., Spruance S. L., Esmann J. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. Arch Dermatol. 1998 Feb;134(2):185–191. doi: 10.1001/archderm.134.2.185. [DOI] [PubMed] [Google Scholar]
  9. Tyring S. K., Douglas J. M., Jr, Corey L., Spruance S. L., Esmann J. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. Arch Dermatol. 1998 Feb;134(2):185–191. doi: 10.1001/archderm.134.2.185. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES